Scholarlink

<p>Heart failure (HF) remains a major global health burden, with rising prevalence and significant morbidity and mortality despite advances in diagnosis and management. Over the past years, the therapeutic landscape of HF has evolved substantially, driven by a growing number of pivotal clinical trials addressing not only heart failure with reduced ejection fraction (HFrEF), but also heart failure with mildly reduced (HFmrEF) and preserved ejection fraction (HFpEF). The following review provides a comprehensive update on key clinical trials published or presented in the recent past such as DIGIT-HF, VICTORIA and VICTOR, STRONG-HF, SUMMIT or STEP-HFpEF trials, highlighting novel pharmacological therapies, patient phenotyping, and treatment of co-morbidities. Special attention is given to trials with practice changing implications and those shaping future guidelines. </p> Graphical Abstract <p>Central illustration:&#xa0;<i>ACEi</i> angiotensin-converting enzyme inhibitor, <i>ARB</i> angiotensin receptor blocker, <i>ARNI</i> angiotensin receptor–neprilysin inhibitor, <i>CV</i> cardiovascular, <i>GDMT</i> guideline-directed medical therapy, <i>GLP-1</i> glucagon-like peptide-1, <i>HFmrEF</i> heart failure with mildly reduced ejection fraction, <i>HFpEF</i> heart failure with preserved ejection fraction, <i>HFrEF</i> heart failure with reduced ejection fraction, <i>HHF</i> hospitalization for heart failure, <i>LVEF</i> left ventricular ejection fraction, <i>MRA</i> mineralocorticoid receptor antagonist, <i>SGLT2i</i> sodium-glucose cotransporter 2 inhibitor, <i>uNa⁺</i> urinary sodium.</p> <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Update on clinical heart failure trials

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月17日

查看全文
  • Julian Hoevelmann,
  • Mert Tokcan,
  • Saarraaken Kulenthiran,
  • Amr Abdin,
  • Charle Viljoen,
  • Michael Böhm

摘要

Heart failure (HF) remains a major global health burden, with rising prevalence and significant morbidity and mortality despite advances in diagnosis and management. Over the past years, the therapeutic landscape of HF has evolved substantially, driven by a growing number of pivotal clinical trials addressing not only heart failure with reduced ejection fraction (HFrEF), but also heart failure with mildly reduced (HFmrEF) and preserved ejection fraction (HFpEF). The following review provides a comprehensive update on key clinical trials published or presented in the recent past such as DIGIT-HF, VICTORIA and VICTOR, STRONG-HF, SUMMIT or STEP-HFpEF trials, highlighting novel pharmacological therapies, patient phenotyping, and treatment of co-morbidities. Special attention is given to trials with practice changing implications and those shaping future guidelines.

Graphical Abstract

Central illustration: ACEi angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, ARNI angiotensin receptor–neprilysin inhibitor, CV cardiovascular, GDMT guideline-directed medical therapy, GLP-1 glucagon-like peptide-1, HFmrEF heart failure with mildly reduced ejection fraction, HFpEF heart failure with preserved ejection fraction, HFrEF heart failure with reduced ejection fraction, HHF hospitalization for heart failure, LVEF left ventricular ejection fraction, MRA mineralocorticoid receptor antagonist, SGLT2i sodium-glucose cotransporter 2 inhibitor, uNa⁺ urinary sodium.